GT BIOPHARMA, INC. Convertible Notes Payable
GT BIOPHARMA, INC. (GTBP) had Convertible Notes Payable of $38.80 million as of 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:ConvertibleNotesPayable · last filed 2022-08-15
- 2021-09-30: Convertible Notes Payable $38.80M.
- 2021-06-30: Convertible Notes Payable $38.80M.
- 2021-02-16: Convertible Notes Payable $38.80M.
- 2020-12-31: Convertible Notes Payable $2.50M.
| Period end | Convertible Notes Payable |
|---|---|
| 2021-09-30 | $38.80M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $38.80M 10-Q/A · filed 2021-12-29 |
| 2021-02-16 | $38.80M 10-Q/A · filed 2021-12-29 |
| 2020-12-31 | $2.50M 10-Q · filed 2022-08-15 |
| 2019-12-31 | $2.50M 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |